Cancer clinical trials in the region Auvergne-Rhône-Alpes

247 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 3 Breast cancer
#NCT06018337
HER2 Low HR Positive Locally Advanced Metastatic Targeted therapy Hormone therapy
Chemotherapy Antibody Drug Conjugates (ADC)
8 main criterias to confirm
Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Institut Sainte Catherine (Avignon), CHU Nîmes / Institut de cancérologie du Gard (Nîmes), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
DualityBio Inc.
Phase 3 Lymphoma
#NCT06006117
B cell lymphoma Marginal zone lymphoma None > 60 ml/min 50-60 ml/min 30-50 ml/min Targeted therapy 1 2 3 or more
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
10 main criterias to confirm
Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand), Centre Hospitalier d'Avignon (Avignon) (and 1 more...)
Organisation de recherche universitaire sur le lymphome
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C Systemic Treatment-Naive PDL1 Negative (< 1%)
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
12 main criterias to confirm
Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Hôpitaux Nord-Ouest - Villefranche-sur-Saône (Gleizé), Centre Hospitalier Universitaire de Nîmes (Nîmes), Centre de Cancérologie du Grand Montpellier (Montpellier)
Amgen
Phase 3 Breast cancer
#NCT05894239
HER2 Positive Locally Advanced Metastatic PIK3CA
Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
7 main criterias to confirm
Institut Sainte Catherine (Avignon)
Hoffmann-La Roche
Phase 3 Breast cancer
#NCT05696626
HER2 Negative HR Positive Locally Advanced Metastatic ESR Targeted therapy Hormone therapy
Other mutation Systemic Treatment-Naive
10 main criterias to confirm
Centre Léon Bérard (Lyon)
Sermonix Pharmaceuticals Inc.
Phase 3 Lung cancer
#NCT05668988
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR Systemic Treatment-Naive
8 main criterias to confirm
Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
Debiopharm International SA
Phase 3 Lung cancer
#NCT05607550
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR Systemic Treatment-Naive
Immunotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
9 main criterias to confirm
Centre Léon Bérard (Lyon), Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon)
ArriVent BioPharma, Inc
Phase 3 Breast cancer
#NCT05296798
HER2 Positive HR Positive Locally Advanced Metastatic
Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
7 main criterias to confirm
Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon), Centre Hospitalier Universitaire de Grenoble (La Tronche), Institut Sainte Catherine (Avignon)
Hoffmann-La Roche
Phase 3 Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic Systemic Treatment-Naive PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%)
EGFR BRAF MET ALK RET ROS-1 NTRK-1/2/3 Other mutation Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
11 main criterias to confirm
Centre Léon Bérard (Lyon), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
Daiichi Sankyo
Phase 3 Breast cancer
#NCT05514054
HER2 Negative HR Positive Localized Hormone therapy
7 main criterias to confirm
Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand), Institut Sainte Catherine (Avignon), Centre de Cancérologie du Grand Montpellier (Montpellier)
Eli Lilly et compagnie